Shares of Omeros Corporation (NASDAQ: OMER), a rising star in the biotech industry, are losing altitude after the company reported first-quarter earnings today. The stock was down 16% earlier this morning, but just 11.4% lower than …
Shares of Omeros Corporation (NASDAQ: OMER) surged nearly 17% on Tuesday after the company announced that the U.S. Food and Drug Administration had granted its lead drug candidate breakthrough therapy designation. OMS721 is …
So make sure to keep an eye on this stock going forward to see if yesterday's move higher lasts. Omeros currently has a Zacks Rank #3 (Hold). A better-ranked med products stock is Abaxis, Inc. ( ABAX) with a Zacks Rank #1 (Strong Buy). …
The report, which was written by people trying to profit from a drop in Omerosstock, questioned whether the biotech has data to back up its positioning of OMS721 as a more convenient, subcutaneous alternative to Alexion’s blockbuster …
Today's Daily Dose brings you news about CEL-SCI's resumption of Multikine trial; Fate Therapeutics' progress with its pipeline; Lipocine's regulatory catalyst to watch out for; Omeros' stock offering; Ophthotech's disappointing results from …
Good news for Omeros Corporation (NASDAQ:OMER) short sellers -- the drug stock is bombing on a wider-than-expected quarterly loss. In addition, the company's revenue came up short of the Street's consensus estimate, though OMER
Omeros Corporation (NASDAQ:OMER) stock was finding some respite in Thursday’s pre-market trading after the biopharma group evidently mounted a defence against short-sellers. In a statement, the company states that it is …